Efficacy of annual zoledronic acid in initial percutaneous kyphoplasty patients with osteoporotic vertebral compression fractures: a 3-year follow-up study
- 18 January 2021
- journal article
- research article
- Published by Springer Science and Business Media LLC in Osteoporosis International
- Vol. 32 (7), 1429-1439
- https://doi.org/10.1007/s00198-020-05816-z
Abstract
Summary This study investigated the efficacy of annual zoledronic acid (ZOL) administration against previously treated recompression vertebral fractures (RVF) and new vertebral fractures (NVF) in initial percutaneous kyphoplasty (PKP) patients with osteoporotic vertebral compression fractures (OVCF) over a 3-year follow-up period. Introduction Although PKP achieves a satisfactory outcome, previously treated RVF and NVF can limit its effectiveness. The annual infusion of ZOL over 3 years can improve fracture protection, particularly in the vertebrae. We hypothesized that ZOL can reduce the incidence of RVFs and/or NVFs, and improve the clinical outcomes of PKP. Methods This was a placebo-controlled, double-blind prospective trial of 154 PKP patients (mean age: 70 years) with OVCFs. Patients were randomly assigned to receive a single infusion of ZOL (5 mg) or placebo (78 ZOL vs. 76 placebo) at 1 week, 12 months, and 24 months after surgery. Patients were followed-up for 36 months. Results ZOL treatment lowered the risk of RVF by ~ 65% over the 36-month period when compared to placebo controls (6.41% in ZOL vs. 18.42% in placebo groups; relative risk, 0.35; 95% CI, 0.13 to 0.92). ZOL also reduced the risk of NVF by ~ 73% (3.85% in ZOL vs. 14.47% in placebo groups; relative risk, 0.27; 95% CI, 0.08 to 0.92). ZOL also significantly reduced the vertebral height lost rate (HLR) at 12, 24, and 36 months. ZOL also improved the visual analog scale (VAS), Oswestry disability index (ODI) scores, and bone mineral density (BMD). Conclusion Annual ZOL administration significantly lowers the risk of RVFs and NVFs, improving the clinical outcome of initial PKP in patients with OVCFs over a 3-year follow-up period. Trial registration ChiCTR2000029307Keywords
Funding Information
- Suzhou Key Clinical Diagnosis and Treatment Technology Project (LCZX202024)
- Kunshan Social Development Science and Technology Project (KS18068)
- Beijing Bethune Charitable Foundation (B19338ES)
This publication has 51 references indexed in Scilit:
- The Efficacy of Bisphosphonates in the Prevention of Vertebral, Hip, and Nonvertebral-Nonhip Fractures in Osteoporosis: A Network Meta-AnalysisSeminars in Arthritis and Rheumatism, 2011
- Recompression of vertebral body after balloon kyphoplasty for osteoporotic vertebral compression fractureEuropean Spine Journal, 2010
- The role of zoledronic acid in the management of osteoporosisClinical Rheumatology, 2010
- Adjacent vertebral failure after vertebroplasty: a biomechanical study of low-modulus PMMA cementEuropean Spine Journal, 2007
- Once-Yearly Zoledronic Acid for Treatment of Postmenopausal OsteoporosisNew England Journal of Medicine, 2007
- An estimate of the worldwide prevalence and disability associated with osteoporotic fracturesOsteoporosis International, 2006
- Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE studyAnnals Of The Rheumatic Diseases, 2006
- Efficacy and safety of balloon kyphoplasty in the treatment of vertebral compression fractures: a systematic reviewEuropean Spine Journal, 2006
- Effects of Oral Ibandronate Administered Daily or Intermittently on Fracture Risk in Postmenopausal OsteoporosisJournal of Bone and Mineral Research, 2004
- The Association of Bone Mineral Density and Depression in an Older PopulationJournal of the American Geriatrics Society, 2001